Skip to content
Back to ERNAW

Ernexa Therapeutics Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
1
Purchases
1
Sales
0
Purchase value
$0.00
Sale value
$0.00

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

1 row is listed but not counted: its filed price fails a plausibility check, or it is not common stock.

Cherington Charles10% owner
4
Filed Feb 17, 2026Period of report Feb 10, 20260001104659-26-016680
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseFeb 10, 2026
Common StockF1F24,000,000$0.50Not counted6,779,440Direct
Filing footnotes · 3
  1. F1These shares and warrants were purchased by the reporting person in the Issuer's follow-on offering pursuant to a prospectus supplement dated February 6, 2026, which closed on February 10, 2026.
  2. F2The combined purchase price in the Offering per share of Common Stock and accompanying warrant was $0.50.
  3. F3The warrants will expire on the earlier of (i) February 10, 2031 or (ii) the 180th calendar day following the public release by the Company of clinical trial data from the first cohort of the Phase 1 study of ERNA-101.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.